The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.
April 4th 2024
Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer.
Nivolumab/Ipilimumab Demonstrates OS Benefit in Advanced NSCLC With Brain Metastases
The combination of nivolumab and ipilimumab provided similar clinical benefit to that of chemotherapy when given as a frontline treatment for patients with advanced non–small cell lung cancer who had stable and treated brain metastases at baseline.
Tiragolumab/Atezolizumab Shows Early First-in-Human Efficacy in Frontline PD-L1+ NSCLC
June 24th 2020Tiragolumab in combination with atezolizumab (Tecentriq) demonstrated early clinical activity and was found to be well tolerated in patients with advanced solid tumors, including those with metastatic non–small cell lung cancer who were PD-L1 positive and had not received prior checkpoint inhibition.
Chaft Crafts Considerations for Restarting Immunotherapy in Lung Cancer
May 19th 2020Jamie E. Chaft, MD, provides insight into IRAEs and immunotherapy restart, considerations for immunotherapy in the pre- and post-operative period, outlines biomarker research in lung cancer, and projects her hopes for the future use of this approach in this space.
Optimal Immunotherapy Sequencing Remains Elusive in Lung Cancer
February 9th 2020The potential therapeutic benefits of immune checkpoint inhibitors as monotherapy as well as in combination with chemotherapy for patients with non–small cell lung cancer depend greatly on the timing of treatment initiation. However, for patients with EGFR, ALK, and other actionable mutations, identifying the optimal combination is a hurdle.
Experts Take Stock of Frontline Immunotherapy Combos in NSCLC
January 9th 2020During an OncLive Peer Exchange program, an international panel of lung cancer experts provided perspective on key findings regarding various immune checkpoint inhibitor (ICI) combinations and data concerning potential biomarkers of response to ICIs in non–small cell lung cancer.
NICE Cites Cost in Deciding Against Atezolizumab for Frontline Advanced Small Cell Lung Cancer
January 7th 2020The United Kingdom’s National Institute for Health and Care Excellence did not recommend granting marketing authorization to atezolizumab (Tecentriq) in combination with carboplatin and etoposide for the treatment of patients with treatment-naïve extensive-stage small cell lung cancer.